Re: PAL: What's New Digest - Oct 2

[Guest guest]

Karl,

Thanks again for this and all your other ongoing valuable links,

articles, and comments.

I have been traveling again and am just trying to catch up. The world

of CLL treatment is a moving target for sure.

Be well

On Oct 2, 2011, at 8:05 AM, karls@lymphomation wrote:

What's New Digest posted to lymphomation.org - Oct 2

===Survivorship

Mother risk: Cancer in Pregnancy: Non-Hodgkin's Lymphoma and Pregnancy

http://bit.ly/opsHJ0

Medscape: Love the Caregiver as Much as the Patient http://bit.ly/r9Y5Ii

ASCO Expert Corner: The Role of a Tumor Board in Cancer Treatment

http://bit.ly/qgg509

Medscape: Chemotherapy Safe to Give During Pregnancy http://bit.ly/qEkTCx

NCCN: Financial Assistance for People with cancer. http://bit.ly/plaBvz

The Spokesman Review: Diagnosed with lymphoma, photographer turned

lens on

himself http://bit.ly/poNwbu

Lymphomation: Tools and Tips from Lymphomation http://bit.ly/ompUde

ASCO: Anti-nausea drugs: Oncology Clinical Practice Guideline Update

http://bit.ly/nCzYxI

===Outcome Reports & Background

MALT - MedWire: 'Excellent' outcomes after H. pylori eradication for

gastric MALT http://bit.ly/nspfIl

Pregnancy - ECCO: Chemo during pregnancy does NOT seem to cause

developmental problems in children http://bit.ly/oCMgXK

NY Presby-Weill Cornell: Two Important Studies Take Us One Step Closer

to

Personalized Lymphoma Therapy http://bit.ly/piqxeo

Blood: BeEAM (bendamustine, etoposide, cytarabine, melphalan) before

autologous stem cell transplantation is safe and effective for

resistant/relapsed lymphoma patients http://bit.ly/pGoqsq

Cancer Care: Update on Lymphoma from the 2011 ASCO Annual Meeting

http://bit.ly/poe5dj

CLL Topic Updates: Bendamustine and Rituxan- relapsed/refractory CLL

Bendamustine http://bit.ly/r3VVGO

PubMED: Utility of positron emission tomography scans in mantle cell

lymphoma http://1.usa.gov/o2pGbN

PubMed: Physical activity for patients undergoing an allogeneic

hematopoietic stem cell transplantation: benefits of a moderate exercise

intervention. http://1.usa.gov/pkpENS

DLBCL- PubMed: The Germinal Center/Activated B-Cell Sub-classification

Has

a Prognostic Impact for Response to Salvage Therapy in Relapsed/

Refractory

DLBCL: A Bio-CORAL Study. http://1.usa.gov/qFylgl

===Videos / Webcasts

NCCN: Video: Talking to patients with a new cancer diagnosis

http://bit.ly/pLqSJj

Patient Power: Personalized Oncology- Where are we now?

===Advocacy and Notices

Drug Shortages and How to address!

www.lymphomation.org/current.htm

BBC: Cancer cost 'crisis' warning from oncologists

http://www.bbc.co.uk/news/health-15032862

Weill-Cornell-lymphoma: Oral Chemotherapy Bill Signed into Law in New

York

State http://bit.ly/rqTnUb

LRF: Philadelphia-Ask the Doctor: Updates on Lymphoma and Treatments

R. , MD Fox Chase Cancer Center 10/12/11

www.lymphomation.org/current.htm

Medscape: Congress Urged To Renew Commitment to Cancer Research

www.lymphomation.org/current.htm

===Clinical Trials

PAL Pipeline of new drugs with links to trials

PAL Trial tools:

- New Trials since Sept 1

- When to Consider Trials?

- Lookup Trials by Type & Treatment Status

- Antibody-based trials

www.lymphomation.org/current.htm

NCI: Which Study Results Are the Most Helpful in Making Cancer Care

Decisions? www.lymphomation.org/current.htm

===PAL Updates

Lookup Trials by Type & Treatment Status

www.lymphomation.org/current.htm

===Food for Thought

University of Leicester: Public ignorant about key messages concerning

diet

and cancer http://bit.ly/rn7DnH

Neurologic blog: Well it worked for me. http://bit.ly/mWpjhJ

Mail ONline: Don't give out cancer drugs if it's just to extend life?

http://bit.ly/odMiIq

MD: Learning the hard way that there is an art to medicine

http://bit.ly/qAEfxv

Pharmagossip: Use of cancer drugs questioned - Health News - NHS Choices

http://bit.ly/quagOH

Pharmagossip: NICE blames Pharma R & D model for spiraling cancer drug

costs

http://bit.ly/qEYeGi

Science Daily: Drug Companies Must Report Clinical Trial Results, Even

When

They Won't Lead to a Product, Experts Urge http://bit.ly/qxsjBP

UCDAVIS: Drug companies must report clinical trial results, even when

they

won't lead to a product http://bit.ly/oiH1XX

Respectful Insolence: Abraham Cherrix still battling Hodgkin's Five

Years

Later http://bit.ly/nhm1Xu

===Technical ... Theory/Preclinical

Science Daily: Pre-Clinical Research may Prove Promising for the

Treatment

of Blood Cancer http://bit.ly/qZ5OMo

Walter and Eliza Hall Institute: Discovery helps explain why chemo

causes

drop in platelet numbers http://bit.ly/npqbuG

All the best,

Karl

Patients Against Lymphoma

See also News and Reports: www.lymphomation.org/current.htm

OR www.facebook.com/lymphomation.PAL (requires facebook account)

<!-- #ygrp-mkp { border: 1px solid #d8d8d8; font-family: Arial;

margin: 10px 0; padding: 0 10px; } #ygrp-mkp hr { border: 1px solid

#d8d8d8; } #ygrp-mkp #hd { color: #628c2a; font-size: 85%; font-

weight: 700; line-height: 122%; margin: 10px 0; } #ygrp-mkp #ads

{ margin-bottom: 10px; } #ygrp-mkp .ad { padding: 0 0; } #ygrp-mkp .ad

p { margin: 0; } #ygrp-mkp .ad a { color: #0000ff; text-decoration:

none; } #ygrp-sponsor #ygrp-lc { font-family: Arial; } #ygrp-sponsor

#ygrp-lc #hd { margin: 10px 0px; font-weight: 700; font-size: 78%;

line-height: 122%; } #ygrp-sponsor #ygrp-lc .ad { margin-bottom: 10px;

padding: 0 0; } a { color: #1e66ae; } #actions { font-family: Verdana;

font-size: 11px; padding: 10px 0; } #activity { background-color:

#e0ecee; float: left; font-family: Verdana; font-size: 10px; padding:

10px; } #activity span { font-weight: 700; } #activity span:first-

child { text-transform: uppercase; } #activity span a { color:

#5085b6; text-decoration: none; } #activity span span { color:

#ff7900; } #activity span .underline { text-decoration:

underline; } .attach { clear: both; display: table; font-family:

Arial; font-size: 12px; padding: 10px 0; width: 400px; } .attach div a

{ text-decoration: none; } .attach img { border: none; padding-right:

5px; } .attach label { display: block; margin-bottom: 5px; } .attach

label a { text-decoration: none; } blockquote { margin: 0 0 0

4px; } .bold { font-family: Arial; font-size: 13px; font-weight:

700; } .bold a { text-decoration: none; } dd.last p a { font-family:

Verdana; font-weight: 700; } dd.last p span { margin-right: 10px; font-

family: Verdana; font-weight: 700; } dd.last p span.yshortcuts

{ margin-right: 0; } div.attach-table div div a { text-decoration:

none; } div.attach-table { width: 400px; } div.file-title a, div.file-

title a:active, div.file-title a:hover, div.file-title a:visited

{ text-decoration: none; } div.photo-title a, div.photo-title

a:active, div.photo-title a:hover, div.photo-title a:visited { text-

decoration: none; } div#ygrp-mlmsg #ygrp-msg p a span.yshortcuts

{ font-family: Verdana; font-size: 10px; font-weight: normal; } .green

{ color: #628c2a; } .MsoNormal { margin: 0 0 0 0; } o { font-size:

0; } #photos div { float: left; width: 72px; } #photos div div

{ border: 1px solid #666666; height: 62px; overflow: hidden; width:

62px; } #photos div label { color: #666666; font-size: 10px; overflow:

hidden; text-align: center; white-space: nowrap; width: 64px; } #reco-

category { font-size: 77%; } #reco-desc { font-size: 77%; } .replbq

{ margin: 4px; } #ygrp-actbar div a:first-child { /* border-right: 0px

solid #000;*/ margin-right: 2px; padding-right: 5px; } #ygrp-mlmsg

{ font-size: 13px; font-family: Arial, helvetica,clean, sans-serif;

*font-size: small; *font: x-small; } #ygrp-mlmsg table { font-size:

inherit; font: 100%; } #ygrp-mlmsg select, input, textarea { font: 99%

Arial, Helvetica, clean, sans-serif; } #ygrp-mlmsg pre, code { font:

115% monospace; *font-size:100%; } #ygrp-mlmsg * { line-height:

1.22em; } #ygrp-mlmsg #logo { padding-bottom: 10px; } #ygrp-mlmsg a

{ color: #1E66AE; } #ygrp-msg p a { font-family: Verdana; } #ygrp-msg

p#attach-count span { color: #1E66AE; font-weight: 700; } #ygrp-reco

#reco-head { color: #ff7900; font-weight: 700; } #ygrp-reco { margin-

bottom: 20px; padding: 0px; } #ygrp-sponsor #ov li a { font-size:

130%; text-decoration: none; } #ygrp-sponsor #ov li { font-size: 77%;

list-style-type: square; padding: 6px 0; } #ygrp-sponsor #ov ul

{ margin: 0; padding: 0 0 0 8px; } #ygrp-text { font-family:

Georgia; } #ygrp-text p { margin: 0 0 1em 0; } #ygrp-text tt { font-

size: 120%; } #ygrp-vital ul li:last-child { border-right: none !

important; } -->